Yohimbe

Introduction Overview

Generic Name

Yohimbe

Brand Name

Yohimbe, Yohimbine HCl, Aphrodyne, Yocon, Yohimbe Bark

Dosage Form

Oral tablets or capsules (variable formulations in supplement form), typically in standardized extracts or Yohimbine hydrochloride

Drug Class

Impotence agents, Alpha-2 adrenergic receptor antagonist

Pharmacokinetics

Absorption:
Yohimbe, primarily administered orally, exhibits moderate absorption in the gastrointestinal tract. Peak plasma concentrations of yohimbine, the active alkaloid constituent, are typically reached within 30 to 90 minutes post-ingestion, although variability exists due to differences in formulation and individual metabolic factors. The oral bioavailability of yohimbine is subject to first-pass metabolism, which may significantly reduce systemic availability. Food intake can influence absorption rates and bioavailability, with some studies indicating delayed absorption when administered with meals.

Distribution:
Upon absorption, yohimbine demonstrates wide distribution throughout body tissues, including crossing the blood-brain barrier, to exert central nervous system effects. Yohimbine is extensively bound to plasma proteins, with an estimated binding of approximately 20-30%, facilitating its distribution in both the central and peripheral nervous systems. The volume of distribution is moderate, reflecting both tissue and plasma compartment distribution.

Metabolism:
Yohimbine undergoes hepatic metabolism primarily via the cytochrome P450 enzyme system, particularly CYP2D6. It is metabolized into several hydroxylated and demethylated metabolites, which vary in pharmacological activity. The extent of metabolism can be influenced by individual genetic polymorphisms in CYP2D6, resulting in variable plasma levels and clinical effects. Metabolic interactions with other drugs that inhibit or induce CYP2D6 can alter yohimbine plasma concentration and efficacy.

Elimination:
The elimination half-life of yohimbine ranges approximately from 0.5 to 2 hours, reflecting relatively rapid clearance. Elimination occurs primarily via renal excretion of parent drug and metabolites. Renal clearance can be affected by kidney function, necessitating dosage adjustments or caution in patients with renal impairment. Yohimbine clearance can also be influenced by hepatic function abnormalities due to its metabolism in the liver. Steady-state plasma concentrations are typically reached within two days of repeated dosing.

Dosage Forms

Available Dosage Forms:
Yohimbe is most commonly available as oral capsules or tablets containing either crude bark extracts or standardized to the alkaloid yohimbine hydrochloride. Typical available forms include:
- Capsules containing standardized yohimbine HCl, in doses ranging from 2 mg to 10 mg per capsule
- Herbal supplement products containing variable amounts of crude Yohimbe bark powder or extract
- Oral tablets with typical doses around 5 mg to 10 mg

Dosages for Adults and Adolescents:
Clinical dosing of yohimbine for its active alkaloid typically ranges from 5 mg to 20 mg per day, divided into two to three doses due to its short half-life. In studies for erectile dysfunction, initial doses often start at 5 mg TID (three times daily), titrated up carefully based on response and tolerability.
Dosages for adolescents are not established and the use is generally not recommended in this population due to lack of safety data.

Specific Patient Populations:
- Renal Impairment: Use with caution due to renal elimination, dosing adjustment may be necessary.
- Hepatic Impairment: Since yohimbine is metabolized by liver enzymes, hepatic dysfunction may alter drug pharmacokinetics.
- Pregnant or Breastfeeding Women: Contraindicated due to potential adverse effects and lack of safety data.
- Patients with cardiovascular, psychiatric disorders, or seizure disorders require cautious use or avoidance due to risk of exacerbating these conditions.

Mechanism Of Action

Yohimbe's primary pharmacologically active compound, yohimbine, functions as a selective alpha-2 adrenergic receptor antagonist. By blocking these presynaptic alpha-2 receptors, yohimbine disinhibits norepinephrine release, resulting in increased sympathetic nervous system activity. This stimulation leads to enhanced peripheral vasodilation and increased blood flow in certain vascular beds, particularly penile tissue, which underlies its historical use in erectile dysfunction.

At the molecular level, inhibition of alpha-2 receptors reduces negative feedback control over norepinephrine secretion from sympathetic nerve terminals, increasing synaptic concentrations of this neurotransmitter. This action also impacts central nervous system pathways controlling mood, arousal, and anxiety, as alpha-2 receptors modulate noradrenergic neuron firing.

Moreover, yohimbine has been shown to influence dopamine release and may interact with serotonergic systems, contributing to its varied neuropsychological effects. The drug's central stimulatory effects have research implications on treating certain psychiatric conditions, although clinical evidence remains limited.

Clinically, yohimbine's mechanism contrasts with phosphodiesterase type 5 inhibitors such as sildenafil, which act downstream by enhancing nitric oxide-mediated vasodilation. Yohimbine exerts a more upstream effect on autonomic neurotransmitter release. Comparative studies reveal that yohimbine may benefit some patients with psychogenic erectile dysfunction but is less effective in vasculogenic causes.

Pharmacological Actions

Selective alpha-2 adrenergic receptor antagonist causing increased norepinephrine release.
Sympathetic nervous system stimulation leading to increased heart rate and peripheral vasodilation.
Facilitation of penile blood flow through enhanced vascular smooth muscle relaxation.
Modulation of central nervous system noradrenergic pathways with potential anxiogenic or sympathomimetic effects.
Potential dopaminergic and serotonergic system interactions influencing mood and behavior.
Mild central nervous system stimulant effects at therapeutic doses.
Can increase sympathetic outflow resulting in increased blood pressure and heart rate.
May improve psychogenic erectile dysfunction via neural pathway modulation.
Possesses limited direct smooth muscle relaxant activity compared to phosphodiesterase inhibitors.
Exerts peripheral vasodilator effects by blocking presynaptic inhibitory receptors.
May produce thermogenic effects influencing metabolism at higher doses.
Potential to lower seizure threshold in susceptible individuals.
Influences autonomic regulation contributing to cardiovascular effects.
Acting as a natural alkaloid, its pharmacological properties differ from synthetically derived erectile dysfunction agents.
Stimulates libido and sexual arousal in some animal models through neurochemical pathways.

Therapeutic Or Clinical Uses

Traditionally used as an aphrodisiac and to enhance sexual performance.
Commonly used as an alternative treatment for psychogenic erectile dysfunction.
Explored as a stimulant to improve physical and cognitive performance, though evidence is limited.
Used in some supplements marketed for weight loss and energy enhancement.
Investigated in veterinary medicine for certain neurological and autonomic dysfunctions.
Used experimentally to assess sympathetic nervous system function.
Occasionally used off-label in treatment of orthostatic hypotension.
Considered in research for adjunct management of depression and anxiety due to central noradrenergic effects.
Employed in some traditional medicine systems for male sexual health support.
No FDA-approved clinical indications; use primarily in supplement and alternative medicine markets.
Limited efficacy data for persistent sexual dysfunction related to antidepressants.
Explored in experimental protocols for addressing substance addiction through modulation of neurotransmitters.
Not recommended during pregnancy or breastfeeding due to unknown safety profile.
Use discouraged in patients with significant cardiovascular or psychiatric disorders due to risk profile.
Should not be used concomitantly with monoamine oxidase inhibitors or other interacting drugs.

Side Or Adverse Effects

Gastrointestinal upset including nausea, vomiting, and abdominal discomfort.
Insomnia and sleep disturbances due to CNS stimulation.
Anxiety, nervousness, and restlessness.
Increased heart rate (tachycardia) and palpitations.
Elevated blood pressure or fluctuations leading to hypertension or hypotension.
Headache and dizziness, sometimes associated with blood pressure changes.
Rash and hypersensitivity reactions reported infrequently.
Tremors and muscle twitching at higher doses.
Convulsions or seizures in predisposed individuals or with overdose.
Aggravation of existing psychiatric conditions, such as anxiety or mood disorders.
Rare reports of severe allergic reactions including facial swelling and respiratory difficulty.
Withdrawal symptoms may occur after abrupt discontinuation after chronic use.
Potential for drug interactions exacerbating toxicity.
Excessive dosing may lead to severe cardiovascular events such as arrhythmias.
Fatigue or weakness following acute autonomic nervous system effects.

Precautions

Always consult with a healthcare provider prior to initiating use, particularly if on concurrent medications.
Inform your healthcare provider of yohimbe use before surgeries or diagnostic tests, especially those involving radioactive substances.
Avoid use in pregnancy or when breastfeeding; use effective contraception during therapy.
Avoid concurrent use with monoamine oxidase inhibitors (MAOIs) to prevent severe hypertensive crises.
Use cautiously or avoid in patients with kidney or liver impairment due to altered metabolism and elimination.
Cautious use or avoidance advised in patients with heart conditions including arrhythmias, coronary artery disease, or uncontrolled hypertension.
Patients with psychiatric disorders such as anxiety, schizophrenia, PTSD, or depression should avoid use unless closely supervised.
Seizure history is a contraindication due to risk of lowering seizure threshold.
Asthma patients should be cautious as yohimbe may exacerbate respiratory conditions.
Avoid driving or operating machinery until individual responses are known due to potential CNS effects.
Potential for significant drug interactions necessitates careful medication history review.
Regular monitoring of blood pressure and heart rate is recommended during use.
Discontinue use if severe side effects or allergic reactions develop.
Use of standardized extracts is preferred over unregulated supplements to ensure consistency and safety.
Pregnancy testing and counseling recommended for women of childbearing potential.

Warnings

Do not use if pregnant or planning to become pregnant due to potential fetal risk.
Risk of severe cardiovascular reactions including hypertensive crises and arrhythmias with improper dosing or drug interactions.
Potential for serious central nervous system effects including seizures.
Use contraindicated with MAO inhibitors due to risk of hypertensive emergency.
Avoid use in individuals with psychiatric disorders unless closely monitored.
Possible exacerbation of anxiety, panic attacks, or psychosis.
Risk of severe allergic reactions including anaphylaxis in rare cases.
Avoid concurrent use with other stimulants or drugs affecting norepinephrine pathways.
Risk of significant blood pressure fluctuations requiring medical supervision.
Not approved or validated by major health authorities for treatment of any disorder.
Risk of adverse interactions with prescription medications necessitates avoidance without medical advice.
Potential for abuse or misuse due to stimulant effects.
Discontinue use immediately if signs of serious adverse reactions appear.
Use only products from reputable manufacturers to avoid contaminants or variability in dosing.
Monitoring by healthcare professionals recommended during prolonged use.

Contraindication

Pregnancy and lactation.
Known hypersensitivity to yohimbe or yohimbine.
Concomitant use with monoamine oxidase inhibitors (MAOIs).
Severe renal or hepatic impairment.
History of seizures or epilepsy.
Severe cardiovascular diseases such as uncontrolled hypertension, arrhythmias, or recent myocardial infarction.
Psychotic disorders and severe anxiety disorders.
Use with other sympathomimetic or stimulant drugs.
Patients scheduled for surgery who cannot disclose yohimbe use.
Known hypersensitivity to any components of yohimbe extracts.
Children and adolescents due to lack of safety data.
Patients with asthma prone to bronchospasm without medical supervision.
Concomitant use with other agents that prolong QT interval.
Patients with history of low blood pressure that may be exacerbated.
Patients with bipolar disorder or severe mood instability.

Drug Interactions

Monoamine oxidase inhibitors (MAOIs) - risk of hypertensive crisis.
Antihypertensive agents - may reduce effectiveness or cause unpredictable blood pressure changes.
Stimulants or sympathomimetic drugs - risk of additive cardiovascular and CNS effects.
Selective serotonin reuptake inhibitors (SSRIs) - potential for serotonin syndrome or increased side effects.
Tricyclic antidepressants - additive sympathomimetic stimulation risk.
Drugs metabolized by CYP2D6 - potential for altered plasma concentrations of yohimbine or concomitant drugs.
Beta blockers - possible antagonism of effects or increased cardiovascular risks.
Antiarrhythmic drugs - risk of arrhythmia exacerbation or QT prolongation.
Anticoagulants and antiplatelet agents - increased risk of bleeding due to blood pressure fluctuations.
Alcohol - increased risk of CNS side effects such as dizziness or sedation.
Herbal products with sympathomimetic properties such as ephedra - increased adverse event risk.
Sedatives or CNS depressants - unpredictable CNS effects.
Drugs causing hypotension - risk of enhanced hypotensive episodes.
Diuretics - potential electrolyte imbalances leading to arrhythmias.
Drugs affecting renal or hepatic function - may alter elimination and increase toxicity risk.

Preparations Of The Drug

Standardized extracts of Yohimbe bark containing specified concentrations of yohimbine hydrochloride.
Oral tablets or capsules typically containing from 2 mg to 10 mg of yohimbine HCl.
Crude powdered bark supplements available in various capsule or tablet formulations.
Liquid extract preparations standardized for yohimbine content designed for dosing flexibility.
Combination products with other herbal or natural supplements marketed for sexual health or weight management.
Formulations may include pure yohimbine HCl for research and clinical use.
Products intended for veterinary use with adjusted dosages.
Supplements formulated with inert excipients for stability and bioavailability.
Commercial preparations vary widely in purity and yohimbine concentration, requiring careful product selection.
Available over-the-counter in many jurisdictions but with variable regulatory oversight.
Some compounding pharmacy preparations prepared for individualized dosing needs.
Topical preparations are generally not available or studied.
Quality-controlled pharmaceutical grade preparations used in clinical trials.
Non-standardized dietary supplements pose risk for under- or overdosing.
Herbal preparations may contain multiple alkaloids aside from yohimbine, influencing effects.